CClinicalTrials.gg
CompletedNCT03474809Updated Aug 13, 2019

Early Diagnostic of Sepsis and Potential Impact on Antibiotic Management Based on Serial.Pancreatic Stone Protein (PSP) Measured Using the AbioScope.

An observational study in Sepsis, sponsored by Abionic SA. Completed at 14 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-13.

Sponsored by Abionic SA · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
296
Ages
18 Years and older
Sex
All
01

Study summary

The main purpose of this study is to compare the early detection of sepsis and the decision, by the Investigator to start or not, or to change, antibiotics in Intensive Care Unit (ICU) patients at high risk of sepsis, based on standard of care (clinical, laboratory and imaging data but not on PSP values), as well as timing of antibiotic de-escalation versus the the retrospective assessment (i.e., at the end of the study) of a First Endpoint Adjudication Committee (EAC) which is aware of the clinical data and of the PSP values but not of the Investigator's decision(s), and of the retrospective assessment of a Second Endpoint Adjudication Committee which is only aware of the PSP values.

This study will follow the site's routine clinical practice for the diagnostic, assessment and treatment of the enrolled patients, with the exception of daily blood samples which will be taken for the PSP measurement using the AbioScope as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein [CRP] and Procalcitonin [PCT]).

02

Conditions studied

  • Sepsis

Browse trials for

Keywords

  • Sepsis, PSP, Abionic
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Critically ill patients at high risk of sepsis admitted to the ICU.

Inclusion criteria

  1. Adult patients (age ≥ 18 years)
  2. Requiring ICU management
  3. At high risk of sepsis (septic patients are excluded)
  4. Expected ICU stay for more than 4 days
  5. Have provided written informed consent or consent is given by the patient's legally designated representative.

Exclusion criteria

Exclusion Criteria:

  1. Patient expected to die within 48 hours of admission to ICU
  2. Patient suffering from or known acute or chronic pancreatitis, pancreatic cancer or admitted after pancreatectomy, but if a patient develops any pancreatic disease during the IUC stay he/she will remain in the study.
04

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
296 participants (actual)
Patient registry
No

Interventions

  • DeviceBlood sampling

    Daily blood samples which will be taken for the PSP measurement using the AbioScope as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).

05

What researchers measure

Primary outcomes

  1. Assessment of the performance of serial PSP values measured using the AbioScope.

    i) To assess the performance of serial PSP values measured using the AbioScope in the early detection of sepsis in ICU patients at high risk of developing sepsis.

    Time frame: Day 1 to Day 30, or until discharge from ICU

06

Study locations

14 sites
  • CH Le Mans, Service de Réanimation Médico Chirurgicale & USC
    Le Mans, 72037, France
  • CHU Limoges, Réanimation Polyvalente
    Limoges, 87042, France
  • CH Lyon-Sud, Services de soins critiques
    Pierre-Bénite, 69495, France
  • Hôpital Bretonneau, CHU de Tours, Médecine Intensive - Réanimation
    Tours, 37044, France
  • Ospedale Santa Maria della Misericordia, Terapia Intensiva
    Perugia, 6156, Italy
  • Ospedale Santa Maria delle Croci, Terapia Intensiva
    Ravenna, 48121, Italy
  • Ospedale Infermi, Dept Anesthesia and ICU
    Rimini, 47921, Italy
  • Ospedale San Giovanni Bosco, Servizio Anestesia e Rianimazione
    Torino, 10154, Italy
  • Bern University Hospital, Universitätsklinik für Intensivmedizin
    Bern, 3010, Switzerland
  • Hopitaux Universitaires de Genève, Service des soins intensifs, Département APSI
    Geneva, 1205, Switzerland
  • Centre Hospitalier Universitaire Vaudois, Service of Adult Intensive Care
    Lausanne, 1011, Switzerland
  • Royal Surrey County Hospital, Intensive Care Medicine
    Guildford, GU2 7XX, United Kingdom
  • University College London Hospitals, Anaesthetics Department
    London, NW1 2BU, United Kingdom
  • Guy's & St Thomas' Hospital, Department of Critical Care
    London, SE1 7EH, United Kingdom
07

References and documents

Publications

  • Pugin J, Daix T, Pagani JL, Morri D, Giacomucci A, Dequin PF, Guitton C, Que YA, Zani G, Brealey D, Lepape A, Creagh-Brown B, Wyncoll D, Silengo D, Irincheeva I, Girard L, Rebeaud F, Maerki I, Eggimann P, Francois B. Serial measurement of pancreatic stone protein for the early detection of sepsis in intensive care unit patients: a prospective multicentric study. Crit Care. 2021 Apr 20;25(1):151. doi: 10.1186/s13054-021-03576-8. PubMed 33879189 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03474809
Lead sponsor
Abionic SA
Responsible party
Sponsor
First posted
Mar 23, 2018
Start date
Jun 14, 2018
Primary completion
Mar 15, 2019
Completion
Mar 15, 2019
Last update
Aug 13, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion